Update on Clinical Aspects of Chronic Obstructive Pulmonary Disease | New England Journal of
Medicine Skip to main content The New England Journal of Medicine homepage Advanced …

Chronic obstructive pulmonary disease (COPD) is a global health problem, and since 2001,
the Global Initiative for Chronic Obstructive Lung Disease (GOLD) has published its strategy …

Das vorliegende Dokument ist eine Neufassung und Aktualisierung der Leitlinie zur
Diagnostik und Therapie von Patienten mit COPD, die die bisherige Version aus dem Jahr …

Abstract The Spanish COPD Guidelines (GesEPOC) were first published in 2012, and since
then have undergone a series of updates incorporating new evidence on the diagnosis and …

Background The sputum microbiome has a potential role in disease phenoty** and risk
stratification in chronic obstructive pulmonary disease (COPD), but few large longitudinal …

Cyclic nucleotide phosphodiesterases (PDEs) catalyse the hydrolysis of cyclic AMP and
cyclic GMP, thereby regulating the intracellular concentrations of these cyclic nucleotides …

As the third leading cause of death in the United States in 2014, chronic obstructive
pulmonary disease (COPD) presents a significant challenge to the health care provider. 1 …

Rationale: Ensifentrine is a novel, selective, dual phosphodiesterase (PDE) 3 and PDE4
inhibitor with bronchodilator and antiinflammatory effects. Replicate phase III trials of …

Chronic obstructive pulmonary disease (COPD) is the third most common cause of death in
the USA. In 2010, the cost of COPD in the USA was projected to be approximately US …

Background Roflumilast reduces exacerbations in patients with severe chronic obstructive
pulmonary disease. Its effect in patients using fixed combinations of inhaled corticosteroids …